AKEBIA THERAPEUTICS, INC. Earnings Per Share, Basic and Diluted
AKEBIA THERAPEUTICS, INC. (AKBA) reported Earnings Per Share, Basic and Diluted of -$0.45 per share for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2021-05-10
- AKEBIA THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.51.
- AKEBIA THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.45.
- AKEBIA THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2020-12-31 was -$0.60.
- AKEBIA THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$0.42.
- AKEBIA THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2020 was -$2.77.
- AKEBIA THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2019 was -$2.36.
- AKEBIA THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2018 was -$2.47.
- AKEBIA THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2017 was -$1.69.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month | Earnings Per Share, Basic and Diluted 12 month as first filed | Earnings Per Share, Basic and Diluted 85 month |
|---|---|---|---|---|---|---|
| 2021-06-30 | -$0.51 derived: net income ÷ weighted average shares · filed 2022-08-04 | -$0.97 derived: net income ÷ weighted average shares · filed 2022-08-04 | ||||
| 2021-03-31 | -$0.45 10-Q · filed 2021-05-10 | |||||
| 2020-12-31 | -$0.60 10-K · filed 2021-02-25 | -$2.77 10-K · filed 2021-02-25 | ||||
| 2020-09-30 | -$0.42 10-K · filed 2021-02-25 | -$2.18 10-Q · filed 2020-11-05 | ||||
| 2020-06-30 | -$1.28 10-K · filed 2021-02-25 | -$1.78 10-Q · filed 2020-08-10 | ||||
| 2020-03-31 | -$0.47 10-Q · filed 2021-05-10 | |||||
| 2019-12-31 | -$0.79 10-K · filed 2021-02-25 | -$2.36 10-K · filed 2021-02-25 | ||||
| 2019-09-30 | -$0.46 10-K · filed 2021-02-25 | -$1.57 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | -$0.49 10-K · filed 2021-02-25 | -$1.11 10-Q · filed 2020-08-10 | ||||
| 2019-03-31 | -$0.62 10-K · filed 2021-02-25 | |||||
| 2018-12-31 | -$0.87 10-K · filed 2020-03-12 | -$2.47 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | -$0.46 10-K · filed 2020-03-12 | -$1.54 10-Q · filed 2019-11-12 | ||||
| 2018-06-30 | -$0.60 10-K · filed 2020-03-12 | -$1.09 10-Q · filed 2019-08-08 | ||||
| 2018-03-31 | -$0.48 10-K · filed 2020-03-12 | |||||
| 2017-12-31 | -$1.69 10-K · filed 2020-03-12 | -$1.77 10-K · filed 2018-03-12 | ||||
| 2017-09-30 | -$0.49 10-Q · filed 2018-11-08 | -$2.11 10-Q · filed 2018-11-08 | ||||
| 2017-06-30 | -$0.53 10-Q · filed 2018-08-08 | -$1.66 10-Q · filed 2018-08-08 | ||||
| 2017-03-31 | -$1.15 10-Q · filed 2018-05-09 | |||||
| 2016-12-31 | -$0.99 10-K · filed 2018-03-12 | -$3.60 10-K · filed 2019-03-26 | ||||
| 2016-09-30 | -$0.96 10-K · filed 2018-03-12 | -$2.61 10-Q · filed 2017-11-08 | ||||
| 2016-06-30 | -$0.95 10-K · filed 2018-03-12 | -$1.65 10-Q · filed 2017-08-08 | ||||
| 2016-03-31 | -$0.70 10-K · filed 2018-03-12 | |||||
| 2015-12-31 | -$0.66 10-K · filed 2017-03-06 | -$1.33 derived: net income ÷ weighted average shares · filed 2018-03-12 | -$1.75 derived: net income ÷ weighted average shares · filed 2018-03-12 | -$2.29 10-K · filed 2018-03-12 | ||
| 2015-09-30 | -$0.68 10-K · filed 2017-03-06 | -$1.09 derived: net income ÷ weighted average shares · filed 2016-11-09 | -$1.62 10-Q · filed 2016-11-09 | -$2.15 derived: net income ÷ weighted average shares · filed 2017-03-06 | ||
| 2015-06-30 | -$0.40 10-K · filed 2017-03-06 | -$0.92 10-Q · filed 2016-08-08 | -$1.43 derived: net income ÷ weighted average shares · filed 2017-03-06 | -$1.91 derived: net income ÷ weighted average shares · filed 2017-03-06 | ||
| 2015-03-31 | -$0.53 10-K · filed 2017-03-06 | -$1.06 derived: net income ÷ weighted average shares · filed 2017-03-06 | -$1.53 derived: net income ÷ weighted average shares · filed 2017-03-06 | -$1.92 derived: net income ÷ weighted average shares · filed 2017-03-06 | ||
| 2014-12-31 | -$0.52 10-K · filed 2016-03-14 | -$1.00 derived: net income ÷ weighted average shares · filed 2017-03-06 | -$1.39 derived: net income ÷ weighted average shares · filed 2017-03-06 | -$8.04 10-K · filed 2017-03-06 | ||
| 2014-09-30 | -$0.47 10-K · filed 2016-03-14 | -$0.86 derived: net income ÷ weighted average shares · filed 2015-11-09 | -$8.16 10-Q · filed 2015-11-09 | -$11.61 derived: net income ÷ weighted average shares · filed 2016-03-14 | ||
| 2014-06-30 | -$0.39 10-K · filed 2016-03-14 | -$9.48 10-Q · filed 2015-08-11 | -$15.07 derived: net income ÷ weighted average shares · filed 2016-03-14 | -$20.75 derived: net income ÷ weighted average shares · filed 2016-03-14 | ||
| 2014-03-31 | -$43.37 10-K · filed 2016-03-14 | -$73.44 derived: net income ÷ weighted average shares · filed 2016-03-14 | -$98.28 derived: net income ÷ weighted average shares · filed 2016-03-14 | -$167.26 derived: net income ÷ weighted average shares · filed 2016-03-14 | -$669.68 10-Q · filed 2014-05-12 | |
| 2013-12-31 | -$13.92 10-K · filed 2015-03-04 | -$25.93 derived: net income ÷ weighted average shares · filed 2016-03-14 | -$119.31 derived: net income ÷ weighted average shares · filed 2016-03-14 | -$126.94 10-K · filed 2016-03-14 | ||
| 2013-09-30 | -$11.92 10-K · filed 2015-03-04 | -$111.47 derived: net income ÷ weighted average shares · filed 2014-11-10 | -$117.94 10-Q · filed 2014-11-10 | |||
| 2013-06-30 | -$103.19 10-K · filed 2015-03-04 | -$109.21 10-Q · filed 2014-08-11 | ||||
| 2013-03-31 | -$3.09 10-K · filed 2015-03-04 | |||||
| 2012-12-31 | -$27.82 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |